Biotech Models, Part II: Early-Stage Companies
The goal is financing through dealmaking, not repeated trips to the equity markets. The problem is how to create a strategy for doing plenty of deals without surrendering the upside.
You may also be interested in...
GSK achieved a first-in-class market oncology launch in 2020, but will have to increase that hit rate in order to fulfil its blockbuster ambitions.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.